Anti-infective Agents Market To Reach $150.6 Billion By 2030

Anti-infective Agents Market Growth & Trends

The global anti-infective agents market size is expected to reach USD 150.6 billion by 2030, registering a CAGR of 1.2% from 2023 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

 Request a free sample copy or view report summary: Anti-infective Agents Market Report

Anti-infective Agents Market Report Highlights

• Antiviral was estimated to be the largest segment with a market share of 53.2% in 2022 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV

• Antibacterial segment is anticipated to register the fastest CAGR of 4.2% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment

• Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record

• Oral route of administration was estimated to be the held largest segment in 2022 owing to new product development and presence of strong product pipeline

• Hospital pharmacy dominated the market with the highest revenue share of 28.8% in 2022  while e-commerce is expected to be the fastest-growing segment during the forecast period

• North America dominated the global industry in 2022 and accounted for the largest share of 37.0% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers

• Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients

• Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

 Anti-infective Agents Market Segmentation

Grand View Research has segmented the global anti-infective agents market on the basis of Type/drug class, route of administration, distribution channel, and region:

Anti-infective Agents Type/Drug Outlook (Revenue, USD Billion, 2018 - 2030)

• Antibacterials

  • Cephalosporins

  • Penicillin

  • Fluoroquinolones

  • Macrolides

  • Carbapenem

  • Others

• Antivirals

• Antifungals

  • Azoles

  • Echinocandins

  • Polyenes

  • Others

Anti-infective Agents Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

• Topical

• Oral

• IV

• Others

Anti-fungal Agents Distribution Channel Outlook  (Revenue, USD Billion, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Specialty Pharmacies

• E-Commerce

• Others

Anti-infective Agents Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Anti-infective Agents Market

• Pfizer Inc.

• Abbott.

• Gilead Sciences, Inc.

• Bristol-Myers Squibb Company

• Merck & Co., Inc.

• Sandoz International GmbH

• B. Braun SE

• Xellia Pharmaceuticals

• Mankind Pharma

• Bayer AG

• AstraZeneca

• Boehringer Ingelheim International GmbH